{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T05:37:45Z","timestamp":1740202665734,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurochir"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>ProGAV and ProGAV2.0 adjustable valves are extensively used for treating hydrocephalus in pediatric patients. This study aims to conduct a comprehensive comparison between these two valves concerning their survival and complication rates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study included all pediatric patients who underwent ProGAV or ProGAV2.0 valve implantation at our neurosurgical clinic from August 2008 to August 2020. A comparative analysis was performed considering age, gender, follow-up duration, complication and survival rates, adjustments, spontaneous adjustments, and adjustment difficulty rates. All valves were followed up for a maximum of 3\u00a0years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Inclusion involved 333 cases (mean age of 5.4\u2009\u00b1\u20095.1\u00a0years; 54.1% males), comprising 173 cases (52.0%) with ProGAV valve implantation and 160 cases (48.0%) with ProGAV 2.0. Early complications within the first month post-implantation were observed in 51 cases (15.3%). No significant differences were noted in valve implantation indications, age distribution, or survival duration (27.1 vs. 27.8\u00a0months, p\u2009=\u20090.629) between the two groups. Predominant indications for implantation were post-hemorrhagic hydrocephalus and aqueduct stenosis for both valve types. Notably, both valves showed non-significantly different explantation rates during the first three years after implantation (34.7% vs. 29.7%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.289). However, there was a significantly higher early post-implantation complication rate (22% vs. 9.4%, <jats:bold>\n                <jats:italic>p<\/jats:italic>\n              <\/jats:bold>\n              <jats:bold>\u2009=\u20090.002<\/jats:bold>), and a significantly increased association with difficulties in valve adjustments and spontaneous adjustments (<jats:bold>\n                <jats:italic>p<\/jats:italic>\n              <\/jats:bold>\n              <jats:bold>\u2009=\u20090.041 and 0.011<\/jats:bold>, respectively). ProGAV2.0 cases displayed notably enhanced clinical and radiological improvement within the initial 6\u00a0months after implantation (<jats:bold>\n                <jats:italic>p<\/jats:italic>\n              <\/jats:bold>\n              <jats:bold>\u2009=\u20090.001 and p\u2009=\u20090.038<\/jats:bold>). Younger children (&lt;\u20092\u00a0years of age) also experienced significantly more valve adjustment difficulties (<jats:italic>p<\/jats:italic>\u2009=\u2009<jats:bold>0.049<\/jats:bold>) and had higher rates of valve explantation (<jats:bold>\n                <jats:italic>p<\/jats:italic>\n              <\/jats:bold>\n              <jats:bold>\u2009&lt;\u20090.001<\/jats:bold>).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The findings of this study highlight the superior performance of the ProGAV2.0 valve in terms of complication rate and maladjustment rate when employed in the treatment of pediatric hydrocephalus. Both valves demonstrated an acceptable survival rate with 65.3% for ProGAV and 71.3% for ProGAV2.0 within three years of implantation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00701-024-06348-9","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T05:43:55Z","timestamp":1731131035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of 333 proGAV\u00ae and proGAV 2.0\u00ae adjustable valves in pediatric hydrocephalus treatment: survival and complication rate assessment"],"prefix":"10.1007","volume":"166","author":[{"given":"Mohammed","family":"Issa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Paggetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Dannehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieke","family":"Ueding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro M.","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"El Damaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"key":"6348_CR1","doi-asserted-by":"publisher","unstructured":"Baumgarten P, Busse L-C, Dinc N, Konczalla J, Senft C, Czabanka MA, Freiman TM (2022) Comparison of long-term functionality and revision rate of two different shunt valves in pediatric and adult patients. In: Brain and Spine, vol Supplement 2, 101566. Elsevier. https:\/\/doi.org\/10.1016\/j.bas.2022.101566","DOI":"10.1016\/j.bas.2022.101566"},{"key":"6348_CR2","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00381-022-05490-y","volume":"38","author":"E Brunner","year":"2022","unstructured":"Brunner E, Schaumann A, Pennacchietti V, Schulz M, Thomale U (2022) Retrospective single-center historical comparative study between proGAV and proGAV2. 0 for surgical revision and implant duration. Childs Nerv Syst 38:1155\u20131163","journal-title":"Childs Nerv Syst"},{"key":"6348_CR3","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1007\/s00701-023-05719-y","volume":"165","author":"L-C Busse","year":"2023","unstructured":"Busse L-C, Dubinski D, Gessler F, Dinc N, Konczalla J, Czabanka M, Senft C, Freiman TM, Baumgarten P (2023) Retrospective comparison of long-term functionality and revision rate of two different shunt valves in pediatric and adult patients. Acta Neurochir 165:2541\u20132549","journal-title":"Acta Neurochir"},{"key":"6348_CR4","unstructured":"Drake JM, Sainte-Rose C (1995) The shunt book. Cambridge, Mass: Blackwell Science xii, p 228: ill.; 23 cm.\u00a0https:\/\/lccn.loc.gov\/94016245"},{"key":"6348_CR5","doi-asserted-by":"publisher","unstructured":"Eckert N (2023) Retrospektiver und prospektiver Vergleich der klinischen Performance des CertasPlus-mit dem proGAV 2.0-Shuntventil zur Behandlung von Hydrocephalus-Patienten. https:\/\/doi.org\/10.53846\/goediss-10104","DOI":"10.53846\/goediss-10104"},{"key":"6348_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3171\/2015.10.PEDS15328","volume":"17","author":"A-F Gebert","year":"2016","unstructured":"Gebert A-F, Schulz M, Schwarz K, Thomale U-W (2016) Long-term survival rates of gravity-assisted, adjustable differential pressure valves in infants with hydrocephalus. J Neurosurg Pediatr 17:544\u2013551","journal-title":"J Neurosurg Pediatr"},{"key":"6348_CR7","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1007\/s00381-021-05162-3","volume":"37","author":"BJ Hall","year":"2021","unstructured":"Hall BJ, Gillespie CS, Hennigan D, Bagga V, Mallucci C, Pettorini B (2021) Efficacy and safety of the Miethke programmable differential pressure valve (proGAV\u00ae 2.0): a single-centre retrospective analysis. Child\u2019s Nerv Syst 37:2605\u20132612","journal-title":"Child's Nerv Syst"},{"key":"6348_CR8","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0140-6736(15)60694-8","volume":"387","author":"KT Kahle","year":"2016","unstructured":"Kahle KT, Kulkarni AV, Limbrick DD, Warf BC (2016) Hydrocephalus in children. The lancet 387:788\u2013799","journal-title":"The lancet"},{"key":"6348_CR9","unstructured":"Miethke C (2014) Shunt and valve technology, in normal pressure hydrocephalus. In: Fritsch M, Kehler U, Meier U (eds) Thieme 9:57\u201383"},{"key":"6348_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2045-8118-12-S1-P36","volume":"12","author":"C Miethke","year":"2015","unstructured":"Miethke C, Knitter T (2015) The new proGAV 2.0-a valve development based on systematical market observation. Fluids Barriers CNS 12:1\u20131","journal-title":"Fluids Barriers CNS"},{"key":"6348_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00701-022-05469-3","volume":"165","author":"SH Pedersen","year":"2023","unstructured":"Pedersen SH, Prein TH, Ammar A, Grotenhuis A, Hamilton MG, Hansen TS, Kehler U, Rekate H, Thomale U-W, Juhler M (2023) How to define CSF overdrainage: a systematic literature review. Acta Neurochir 165:429\u2013441","journal-title":"Acta Neurochir"},{"key":"6348_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3171\/2015.6.PEDS14670","volume":"17","author":"J Riva-Cambrin","year":"2016","unstructured":"Riva-Cambrin J, Kestle JR, Holubkov R, Butler J, Kulkarni AV, Drake J, Whitehead WE, Wellons JC, Shannon CN, Tamber MS (2016) Risk factors for shunt malfunction in pediatric hydrocephalus: a multicenter prospective cohort study. J Neurosurg Pediatr 17:382\u2013390","journal-title":"J Neurosurg Pediatr"},{"key":"6348_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3171\/2008.11.PEDS08154","volume":"3","author":"V Rohde","year":"2009","unstructured":"Rohde V, Haberl E-J, Ludwig H, Thomale U-W (2009) First experiences with an adjustable gravitational valve in childhood hydrocephalus. J Neurosurg Pediatr 3:90\u201393","journal-title":"J Neurosurg Pediatr"},{"key":"6348_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00381-012-1956-9","volume":"29","author":"U-W Thomale","year":"2013","unstructured":"Thomale U-W, Gebert AF, Haberl H, Schulz M (2013) Shunt survival rates by using the adjustable differential pressure valve combined with a gravitational unit (proGAV) in pediatric neurosurgery. Childs Nerv Syst 29:425\u2013431","journal-title":"Childs Nerv Syst"},{"key":"6348_CR15","doi-asserted-by":"publisher","first-page":"ons245","DOI":"10.1227\/NEU.0b013e318214a809","volume":"68","author":"AK Toma","year":"2011","unstructured":"Toma AK, Tarnaris A, Kitchen ND, Watkins LD (2011) Use of the proGAV shunt valve in normal-pressure hydrocephalus. Oper Neurosurg 68:ons245\u2013ons249","journal-title":"Oper Neurosurg"}],"container-title":["Acta Neurochirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-024-06348-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00701-024-06348-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-024-06348-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:01:29Z","timestamp":1740171689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00701-024-06348-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6348"],"URL":"https:\/\/doi.org\/10.1007\/s00701-024-06348-9","relation":{},"ISSN":["0942-0940"],"issn-type":[{"type":"electronic","value":"0942-0940"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective, single-center study was approved by the institutional ethical committee (S-084\/2022) and was conducted in concordance with the Declaration of Helsinki and its amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Obtained from coauthors after agreement of all included patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"447"}}